Self-enhancing, pharmacologically controllable expression systems

US6482618B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Rolf Mueller · Ingolstadt, DE
• Hans-Harald Sedlacek · Marburg, DE

Key dates

• Filing date: Apr 4, 2002
• Grant date: Nov 19, 2002
• Expiry date: Apr 4, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/635
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a nucleic acid construct which constitutes a self-enhancing expression system and which comprises the following components:at least one first structural gene that encodes an active compound;at least one second structural gene that encodes a transcription factor protein; andat least one activation sequence comprised of at least one sequence that binds the transcription factor protein and at least one promoter sequence;wherein each activation sequence activates the expression of a structural gene and the expression of the transcription factor protein; and to the use of the nucleic acid construct for preparing a drug for treating diseases.